Clinical trials: IgG4-Related Diseases
IgG4-related Disease
Characterizing IgG4-RD With 68Ga-FAPI PET/CT
68Ga-FAPI has been developed as a tumor-targeting agent as fibroblast activation protein is overexpressed in cancer-associated fibroblasts and some inflammation,such as IgG4-related disease.And it might be more sensitive than FDG…
- Trial name
- NCT04125511
- Testing
- 68Ga-FAPI
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking Union Medical College Hospital
IgG4 Related Disease
A Phase 3 Study of Obexelimab in Patients With IgG4-Related Disease
This study aims to examine the efficacy and safety of obexelimab for the prevention of flare of IgG4-related disease (IgG4-RD)
- Trial name
- INDIGO (NCT05662241)
- Testing
- Obexelimab
- Where
- 65 sites in United States, Argentina and 13 more
- Volunteers
- 194 people
- Sponsor
- Zenas BioPharma (USA), LLC
IgG4 Related Disease
Tripterygium Wilfordii Plus Prednisone for Active IgG4-Related Disease
The goal of this clinical trial is to learn if tripterygium wilfordii added to prednisone can treat active IgG4-related disease (IgG4-RD) in adults 45 to 80 years of age. Women in the study must be postmenopausal.
- Trial name
- NCT07878585
- Testing
- Prednisone, tripterygium wilfordii
- Where
- China
- Volunteers
- 74 people
- Sponsor
- Peking Union Medical College Hospital
Autoimmune Disease
18F-FDG PET/CT for IgG4-Related Disease
This is an open-label study to investigate the diagnostic performance of 18F-FDG PET/CT (positron emission tomography/computed tomography) in evaluation of patients with IgG4-related disease.
- Trial name
- NCT01665196
- Testing
- 18F-FDG
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking Union Medical College Hospital
IgG4 Related Disease
An Exploratory Clinical Study on the Safety and Efficacy of CD19/BCMA CAR-NK in the Treatment of Relapsed and Refractory IgG4-related Disease
A single arm, open-label pilot study is designed to determine the safety and effectiveness of CD19/BCMA CAR NK cells (KN5601) in patients with IgG4 related diseases.
- Trial name
- NCT07298590
- Testing
- CD19/BCMA CAR NK
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Changhai Hospital
IgG4-related Disease
Study of Sirolimus in IgG4-related Disease
gG4-related disease (IgG4-RD) is a newly recognized systemic autoimmune disease that can involve the pan-creatobiliary tract, retroperitoneum/aorta, head and neck region, and salivary glands, et al.
- Trial name
- NCT05746689
- Testing
- Sirolimus
- Volunteers
- 20 people
- Sponsor
- Peking University International Hospital
Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathies
Early Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases
Main purpose: To evaluate the safety of UTAA09 injection in the treatment of relapsed/refractory (R/R) autoimmune disease (AID).
- Conditions
- Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathies, Systemic Sclerosis, IgG4 Related Disease
- Trial name
- NCT06361745
- Testing
- T cell injection targeting CD19 chimeric antigen receptor
- Where
- China
- Volunteers
- 10 people
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
IgG4-related Disease
Short-term Glucocorticoid Combined with MMF for IgG4-RD
Comparison of short-term glucocorticoid monotherapy and short-term glucocorticoid combined with MMF in the treatment of IgG4 Related Disease
- Trial name
- NCT06663618
- Testing
- prednison, Mycophenolate mofetil
- Where
- China
- Volunteers
- 63 people
- Sponsor
- Wen Zhang
IgG4-RD
Study to Evaluate the Effect of XmAb®5871 on Disease Activity in Patients With IgG4-Related Disease (RD)
The purpose of this Phase 2 study is to investigate the effect of XmAb5871 on IgG4-Related Disease (RD) activity
- Trial name
- NCT02725476
- Testing
- XmAb5871
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Xencor, Inc.
AMG 335 Expanded Access Program for IgG4-Related Disease
Expanded access requests for AMG 335 may be considered for adult patients with a confirmed diagnosis of IgG4-related disease. To request access, use Responsible Party contact information provided in this record.
- Trial name
- NCT06590051
- Testing
- UPLIZNA
- Sponsor
- Amgen
IgG4-related Disease
Plasmablast Detection From IgG4-Related Disease Patients
IgG4-related disease (IgG4-RD) is an immune-mediated, fibro-inflammatory disease that leads to tissue damage, organ dysfunction and, if untreated, to organ failure.
- Trial name
- NCT03466970
- Where
- 2 sites in Israel
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Meir Medical Center
IgG4 Related Disease
Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease
ACE1831 is an off-the-shelf, allogeneic gamma delta T (gdT) cell therapy derived from healthy donors, that is under investigation for the treatment in subjects with Immunoglobulin G4 Related Disease (IgG4-RD)
- Trial name
- NCT07061938
- Testing
- ACE1831, Lymphodepleting chemotherapy
- Where
- 11 sites in United States, China and 1 more
- Volunteers
- 34 people
- Sponsor
- Acepodia Biotech, Inc.
IgG4-Related Diseases
Key Mechanisms of Abnormal T Cell Activation and Differentiation in IgG4-Related Ophthalmic Disease
IgG4-related disease (IgG4-RD) is a newly recognized chronic inflammatory condition caused by immune system dysfunction. It is characterized by the infiltration of IgG4+ plasma cells, dense fibrosis, and inflammation involving…
- Trial name
- NCT06655831
- Volunteers
- 20 people
- Sponsor
- Peking University Third Hospital
Recurrent or Refractory Systemic Lupus Erythematosus, Recurrent or Refractory IgG4 Related Diseases
the Safety and Efficacy of Targeted BCMA In Vivo LV Injection for Recurrent or Refractory Autoimmune Diseases
This study is designed as a single arm, open label, single center clinical trial to evaluate the safety, tolerability, efficacy, pharmacokinetic or pharmacodynamic characteristics of the investigational drug V001-BCMA in…
- Conditions
- Recurrent or Refractory Systemic Lupus Erythematosus, Recurrent or Refractory IgG4 Related Diseases, Recurrent or Refractory Systemic Sclerosis, Recurrent or Refractory Idiopathic Inflammatory Myopathy
- Trial name
- NCT07339540
- Testing
- V001-BCMA
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Tongji Hospital
Immunoglobulin G4 Related Disease
A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease
This is a Phase 3, parallel group, 2-arm, randomized, double blind, placebo-controlled, 52-week treatment study to assess the efficacy and safety of rilzabrutinib as a treatment for adult patients with active IgG4-RD.
- Trial name
- RILIEF (NCT07190196)
- Testing
- Rilzabrutinib, Glucocorticoid
- Where
- 95 sites in United States, Argentina and 17 more
- Volunteers
- 124 people
- Sponsor
- Sanofi
Retroperitoneal Fibrosis, Autoimmune Pancreatitis
Rituximab in IgG4-RD: A Phase 1-2 Trial
The primary objective of this study is to evaluate the safety and effectiveness of rituximab in IgG4-RD.
- Conditions
- Retroperitoneal Fibrosis, Autoimmune Pancreatitis, Sialadenitis, Pseudotumor
- Trial name
- NCT01584388
- Testing
- Rituximab
- Volunteers
- 30 people
- Sponsor
- Massachusetts General Hospital
Immunoglobulin G4-Related Disease
Study of the C5a/C5aR1 Axis in IgG4-associated Disease: a Potential Therapeutic Target
This is a monocentric, comparative, cross-sectional, case-control study seeking to identify abnormalities of the C5a-C5aR1 axis between a population of patients with active IgG4-associated disease (MAG4) and two control groups…
- Trial name
- C5-MAG4 (NCT06270524)
- Testing
- Blood sampling
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Assistance Publique Hopitaux De Marseille
Rare Diseases, Amyloidosis
Institutional Registry of Rare Diseases
The goal of this observational study is to create a single macro registry system with data collection on common clinical features, grouping the different rare diseases (RD).
- Conditions
- Rare Diseases, Amyloidosis, Sarcoidosis, Phacomatosis
- Trial name
- NCT06573723
- Where
- Argentina
- Volunteers
- 380 people
- Sponsor
- Hospital Italiano de Buenos Aires
IgG4-related Disease
BCT301 in Treating Refractory/Recurrent IgG4-related Disease
This is an investigator initiated trial to assess the safety and efficacy of BCT301 cell Injection (CAR-iT cells derived from chemically induced pluripotent stem cells) in patients with refractory/recurrent IgG4-related disease.
- Trial name
- NCT07793903
- Testing
- BCT301 Cell Injection
- Volunteers
- 6 people
- Sponsor
- Peking University Third Hospital
Immunoglobulin G4 Related Sclerosing Disease
Leflunomide for Maintenance of Remission in IgG4 Related Disease
The study has been designed as a 12-month, open-label, randomized, controlled study comparing the use of prednisone mono-therapy and prednisone and leflunomide combination therapy in treating patients with IgG4-related disease.
- Trial name
- NCT02703194
- Testing
- Prednisone, Leflunomide
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Chinese PLA General Hospital